Cardiotoxicity of Cancer Therapies
Overview
Affiliations
Cardiotoxicity is a known complication of many cancer therapies. While the cardiotoxicity of established agents such as anthracyclines, antimetabolites, and alkylating agents is well known, it is important to realize that newer anticancer therapies such as tyrosine kinase inhibitors, angiogenesis inhibitors, and checkpoint inhibitors are also associated with significant adverse cardiovascular effects. Echocardiography, magnetic resonance imaging, and radionuclide imaging have been used to identify these complications early and prevent further consequences. We will discuss the different classes of cancer therapeutic agents that cause cardiotoxicity, the mechanisms that lead to these effects, and strategies that can be used to prevent the cardiac morbidity and mortality associated with their use.
Szwed M, Poczta-Krawczyk A, Kania K, Wiktorowski K, Podsiadlo K, Marczak A Int J Mol Sci. 2025; 26(3).
PMID: 39940670 PMC: 11817011. DOI: 10.3390/ijms26030901.
Salloum F, Tocchetti C, Ameri P, Ardehali H, Asnani A, de Boer R JACC CardioOncol. 2024; 5(6):715-731.
PMID: 38205010 PMC: 10774781. DOI: 10.1016/j.jaccao.2023.08.003.
Losartan Reduces Remodeling and Apoptosis in an Adriamycin-Induced Cardiomyopathy Rat Model.
Kim H, Kim K, Lee H, Hong Y J Chest Surg. 2023; 56(5):295-303.
PMID: 37574884 PMC: 10480395. DOI: 10.5090/jcs.23.044.
Serum Copeptin in Cardiooncology Practice: Review of Pathophysiological and Clinical Implications.
Yalta K, Yetkin E, Yalta T Balkan Med J. 2023; 40(2):82-92.
PMID: 36883738 PMC: 9998837. DOI: 10.4274/balkanmedj.galenos.2023.2023-2-14.
NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful.
Mauro A, Mezzaroma E, Toldo S, Melendez G, Franco R, Lesnefsky E Transl Res. 2022; 252:9-20.
PMID: 35948198 PMC: 9839540. DOI: 10.1016/j.trsl.2022.08.004.